Condition: Ovarian Cancer · Sponsor: Theolytics Limited
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
This description comes directly from the study's public registry record.
Clinical Trials · +441865607020 · clinicaltrials@theolytics.com
Always discuss trial participation with your own doctor first.
| Centro Integral Oncológico Clara Campal (CIOCC) Hospital | Madrid, Spain | Recruiting |
| The Beatson West of Scotland Cancer Centre | Glasgow, Scotland, United Kingdom | Recruiting |
| Imperial College Healthcare NHS Trust, Hammersmith Hospital | London, United Kingdom | Recruiting |
| Oxford University Hospitals NHS Foundation Trust, Churchill Hospital | Oxford, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06618235